TNFSF13B and synovial sarcoma: Iguratimod, a novel anti-rheumatic drug, targets the key regulatory kinase TEC in B cell function, inhibiting BAFF-induced B cell activation and plasma cell differentiation, thereby reducing autoantibody production and more effectively alleviating SS symptoms (159).